<DOC>
	<DOC>NCT00797667</DOC>
	<brief_summary>A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.</brief_summary>
	<brief_title>MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Patient is 18 years of age or older Patient has had a history of migraine with or without aura Patient is able to complete study questionnaire(s) and paper diary Patient is pregnant or breastfeeding, or is a female expecting to conceive within the projected duration of the study Patient has basilar or hemiplegic migraine headache, hepatitis or psychiatric conditions Patient was older than 50 years of age at migraine onset History of gastric or small intestinal surgery or has a disease that causes malabsorption Patient has heart attack, unstable angina, coronary artery bypass surgery or other revascularization procedure, stroke, or transient ischemic attack 3 months before starting the study Currently participating or has participated in a study with an investigational compound or device within 30 days of starting the study Currently participating in a study with MK0974 or MK3207</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>